Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ruth Plummer

Showing results (81-90 of 161) with videos related to

Pageof 17
Sort By:
International Journal of Cancer|July 17, 2015
High-resolution imaging for the detection and characterisation of circulating tumour cells from patients with oesophageal, hepatocellular, thyroid and ovarian cancersBarry M Dent, Laura F Ogle, Rachel L O'Donnell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2009
Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastomaRachel A Daniel, Agata L Rozanska, Huw D Thomas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 15, 2022
A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced CancerRobert Jones, Ruth Plummer, Victor Moreno, et al.
Investigational New Drugs|June 13, 2012
Phase I study of PM00104 (Zalypsis®) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumorsChristophe Massard, Jane Margetts, Nadia Amellal, et al.
Lung Cancer (Amsterdam, Netherlands)|December 11, 2021
A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancerRuth Plummer, Emma Dean, Hendrik-Tobias Arkenau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 4, 2010
Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumorsTimothy A Yap, Laura Vidal, Jan Adam, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|July 30, 2023
Early switch to oral antibiotic therapy in patients with low-risk neutropenic sepsis (EASI-SWITCH): a randomized non-inferiority trialVicky Coyle, Caroline Forde, Danny F McAuley, et al.
British Journal of Cancer|April 18, 2019
A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumoursGabriel Mak, Jean-Charles Soria, Sarah P Blagden, et al.
Cancer Chemotherapy and Pharmacology|August 6, 2015
Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumoursRuth Plummer, Helen Swaisland, Karin Leunen, et al.
British Journal of Cancer|May 17, 2025
The DNA-PK inhibitor AZD7648 alone or combined with pegylated liposomal doxorubicin in patients with advanced cancer: results of a first-in-human Phase I/IIa studyTimothy A Yap, Patricia LoRusso, Rowan E Miller, et al.
Pageof 17

Showing results (81-90 of 161) with videos related to

Sort By:
Pageof 17
International Journal of Cancer|July 17, 2015
High-resolution imaging for the detection and characterisation of circulating tumour cells from patients with oesophageal, hepatocellular, thyroid and ovarian cancersBarry M Dent, Laura F Ogle, Rachel L O'Donnell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2009
Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastomaRachel A Daniel, Agata L Rozanska, Huw D Thomas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 15, 2022
A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced CancerRobert Jones, Ruth Plummer, Victor Moreno, et al.
Investigational New Drugs|June 13, 2012
Phase I study of PM00104 (Zalypsis®) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumorsChristophe Massard, Jane Margetts, Nadia Amellal, et al.
Lung Cancer (Amsterdam, Netherlands)|December 11, 2021
A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancerRuth Plummer, Emma Dean, Hendrik-Tobias Arkenau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 4, 2010
Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumorsTimothy A Yap, Laura Vidal, Jan Adam, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|July 30, 2023
Early switch to oral antibiotic therapy in patients with low-risk neutropenic sepsis (EASI-SWITCH): a randomized non-inferiority trialVicky Coyle, Caroline Forde, Danny F McAuley, et al.
British Journal of Cancer|April 18, 2019
A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumoursGabriel Mak, Jean-Charles Soria, Sarah P Blagden, et al.
Cancer Chemotherapy and Pharmacology|August 6, 2015
Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumoursRuth Plummer, Helen Swaisland, Karin Leunen, et al.
British Journal of Cancer|May 17, 2025
The DNA-PK inhibitor AZD7648 alone or combined with pegylated liposomal doxorubicin in patients with advanced cancer: results of a first-in-human Phase I/IIa studyTimothy A Yap, Patricia LoRusso, Rowan E Miller, et al.
Pageof 17